Health Canada approves Xcopri to treat partial offset seizures – Paladin Labs

SK Biopharmaceuticals said that Health Canada granted a Notice of Compliance for Xcopri (ingredient: cenobamate), its epilepsy drug, approving its application for marketing authorization in Canada. Paladin Labs, a local pharmaceutical company, will be in charge of commercializing the product in Canada. Xcopri is the first locally-developed epilepsy drug to score FDA approval, with the entire drug development process from […]